BFO
DNA icon

Boston Family Office’s Ginkgo Bioworks DNA Stock Holding History

Boston Family Office’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-563
Closed -$26K – 268
2024
Q1 		$26K Hold
563
– – ﹤0.01% 263
2023
Q4 		$38K Sell
563
-7,500
-93% -$459K ﹤0.01% 259
2023
Q3 		$584K Buy
8,063
+38
+0.5% +$3.04K 0.05% 173
2023
Q2 		$598K Hold
8,025
– – 0.05% 177
2023
Q1 		$426K Hold
8,025
– – 0.03% 205
2022
Q4 		$542K Buy
+8,025
New +$738K 0.05% 189

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Family Office's DNA Position: Q2 2024 in Review

Boston Family Office sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 563 shares — an estimated $26K sold.

Boston Family Office first reported a position in DNA in Q4 2022 and held it in 6 quarters. The position peaked at $598K in Q2 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Boston Family Office reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Boston Family Office sold 563 Ginkgo Bioworks shares in Q2 2024, an estimated $26K.
  • Boston Family Office first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 6 quarters.
  • Boston Family Office's Ginkgo Bioworks position peaked at $598K in Q2 2023.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Boston Family Office's 13F filing for Q2 2024, filed 12 Aug 2024.